Cancer – S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
What is the goal of this study?
The goal of this study is to answer the following question: does adding nivolumab to standard chemotherapy extend your time without disease more than or less than if we add brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and for up to ten years after you stop taking these drugs to treat the cancer.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are 12 years of age or older
- Have newly diagnosed advanced stage classical hodgkin lymphoma
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.